Operating Lease, Right-of-Use Asset in USD of ELITE PHARMACEUTICALS INC /NV/ from Q1 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly Operating Lease, Right-of-Use Asset history and change rate from Q1 2019 to Q3 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $1.77M, a 15.2% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $1.77M -$318K -15.2% 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 $1.89M -$335K -15.1% 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 $2M -$355K -15.1% 31 Mar 2025 10-Q 14 Nov 2025
Q4 2024 $2.11M +$2.08M +7947% 31 Dec 2024 10-Q 13 Feb 2025
Q3 2024 $2.09M +$2.09M +109907% 30 Sep 2024 10-Q 14 Nov 2024
Q2 2024 $2.22M +$2.21M +29419% 30 Jun 2024 10-Q 14 Aug 2024
Q1 2024 $2.36M +$2.34M +17931% 31 Mar 2024 10-K 30 Jun 2025
Q4 2023 $26.2K +$7.73K +41.8% 31 Dec 2023 10-Q 14 Feb 2024
Q3 2023 $1.9K -$22K -92% 30 Sep 2023 10-Q 14 Nov 2023
Q2 2023 $7.53K -$973K -99.2% 30 Jun 2023 10-Q 14 Aug 2023
Q1 2023 $13.1K -$1.02M -98.7% 31 Mar 2023 10-K 01 Jul 2024
Q4 2022 $18.5K -$1.06M -98.3% 31 Dec 2022 10-Q 14 Feb 2023
Q3 2022 $23.9K -$1.12M -97.9% 30 Sep 2022 10-Q 14 Nov 2022
Q2 2022 $981K -$219K -18.3% 30 Jun 2022 10-Q 15 Aug 2022
Q1 2022 $1.03M +$817K +381% 31 Mar 2022 10-K 29 Jun 2023
Q4 2021 $1.08M +$870K +410% 31 Dec 2021 10-Q 14 Feb 2022
Q3 2021 $1.14M +$878K +333% 30 Sep 2021 10-Q 15 Nov 2021
Q2 2021 $1.2M +$886K +282% 30 Jun 2021 10-Q 16 Aug 2021
Q1 2021 $215K -$149K -40.9% 31 Mar 2021 10-K 29 Jun 2022
Q4 2020 $212K -$200K -48.5% 31 Dec 2020 10-Q 16 Feb 2021
Q3 2020 $263K -$197K -42.7% 30 Sep 2020 10-Q 16 Nov 2020
Q2 2020 $314K -$194K -38.2% 30 Jun 2020 10-Q 14 Aug 2020
Q1 2020 $363K -$191K -34.4% 31 Mar 2020 10-K 14 Jun 2021
Q4 2019 $412K 31 Dec 2019 10-Q 10 Feb 2020
Q3 2019 $460K 30 Sep 2019 10-Q 12 Nov 2019
Q2 2019 $507K 30 Jun 2019 10-Q 09 Aug 2019
Q1 2019 $554K 02 Apr 2019 10-Q 09 Aug 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.